On this page
Key takeaways
• A 1,000 mg oral dose of unformulated fisetin produces a plasma peak of just 9.97 ng/ml (~35 nM) in healthy adults (1). This is 30 to 150-fold below the 1–5 μM window at which fisetin clears senescent cells in cell culture.
• Fisetin is undetectable in plasma beyond two hours after an oral dose (1). There is no accumulation with daily dosing.
• Fisetin is rapidly metabolised to geraldol — a methylated active metabolite that circulates at higher concentrations than the parent compound (3,4).
• Formulation strategies (hydrogel, liposomal, nano-particle) can improve Cmax substantially — the Krishnakumar 2022 hydrogel formulation showed a 23-fold peak increase (1).
• Co-ingestion with dietary fat is the simplest practical intervention for improving unformulated capsule absorption.
• The bioavailability ceiling is the editorial floor for the entire fisetin conversation. Every efficacy claim must be read against this ceiling.
Quick answer
Fisetin is poorly bioavailable when taken orally as an unformulated capsule. The only published human pharmacokinetic study (Krishnakumar 2022) reported that a 1,000 mg dose produced a peak plasma concentration of 9.97 ng/ml — roughly 30 to 150 times below the concentration that produces senolytic effects in cell culture (1). Fisetin is rapidly metabolised, has a short plasma half-life, and does not accumulate with daily dosing. Formulation strategies can meaningfully improve absorption — a hydrogel formulation in the same study produced a 23-fold higher peak. Reading fisetin efficacy claims against this pharmacokinetic ceiling is essential. This article walks through the absorption, metabolism, and excretion in detail. For the practical dose consequences, see our dedicated dosage article.
The Krishnakumar 2022 study — the load-bearing paper
The Krishnakumar 2022 study in the Journal of Nutritional Science is the load-bearing pharmacokinetic paper for the fisetin field, and the single reference from which almost all clinical bioavailability conversation derives (1).
The design was a randomised double-blind crossover in 15 healthy adults. Each participant received two treatments in random order, separated by a 10-day washout: 1,000 mg of unformulated fisetin (a standardised smoke-tree extract) and a hybrid-hydrogel-formulated fisetin (marketed subsequently as FF-20) delivering 192 mg of fisetin. Both treatments were administered as a single oral dose with a small amount of water in the fasted state. Plasma was sampled at 0, 0.5, 1, 2, 4, 6, 8, and 12 hours.
The unformulated arm produced a peak plasma fisetin concentration (Cmax) of 9.97 ng/ml, reached at approximately one hour. The area under the plasma concentration-time curve (AUC0–12h) was small. Fisetin was undetectable in most participants at four hours and in all participants by six hours. The plasma pharmacokinetic profile was a brief low bump followed by rapid clearance — the classical profile of a poorly absorbed, rapidly metabolised flavonoid.
The hydrogel-formulated arm — despite delivering only 192 mg of fisetin — produced a Cmax 23-fold higher and an AUC 27-fold higher than the unformulated 1,000 mg arm. This is the proof-of-principle that formulation can meaningfully change fisetin’s pharmacokinetic profile. It is also the reason we treat unformulated capsules and enhanced formulations as pharmacologically distinct — the biology may be the same, but what reaches the bloodstream is not.
Why absorption is poor — the absorption biology
Three pharmaceutical properties of fisetin conspire to produce low oral bioavailability.
1. Poor aqueous solubility
Fisetin has intrinsic aqueous solubility below 1 μg/ml at physiological pH — meaning that in the aqueous intestinal lumen, most of an oral dose remains undissolved and cannot be absorbed. This is a solubility-limited absorption profile: the amount that can enter the enterocyte is capped by how much can dissolve, not by how much is present.
2. Extensive first-pass metabolism
Fisetin that does dissolve and enter the enterocyte is subjected to rapid Phase I and Phase II metabolism in the intestinal wall and liver (3,4). Phase I methylation produces geraldol (3-methoxyfisetin), which retains substantial biological activity — geraldol has been reported as more cytotoxic than the parent in some cell-culture assays (3). Phase II conjugation via UGT (glucuronidation) and SULT (sulphation) enzymes produces fisetin conjugates that circulate in plasma but are largely biologically inactive. The result is that most fisetin absorbed from the gut is rapidly converted to methylated, glucuronidated, or sulphated forms before it reaches systemic circulation.
3. Rapid biliary elimination
The metabolites and any remaining parent compound are eliminated predominantly via biliary excretion with subsequent enterohepatic recirculation, producing the short, low-amplitude plasma profile observed in the Krishnakumar study (1). Renal excretion contributes a smaller share. The terminal half-life of unformulated fisetin in humans is under two hours by plasma measurement.
Together, these three factors — poor solubility, extensive first-pass metabolism, and rapid elimination — produce the absorption ceiling. Doubling the oral dose does not double the plasma peak; it produces a disproportionately smaller absorption gain because the solubility-limited absorption saturates rapidly.
The geraldol problem — the metabolite matters
Within minutes of oral absorption, fisetin is O-methylated to geraldol. In the Krishnakumar 2022 study, plasma geraldol concentrations exceeded plasma fisetin concentrations within the first hour (1) — meaning most of what circulates after an oral fisetin dose is not fisetin itself but its metabolite. Touil and colleagues (2011) reported that geraldol was actually more cytotoxic than fisetin against Lewis lung carcinoma cells in vitro (3), suggesting that some of fisetin’s biological activity in vivo may belong to the metabolite rather than the parent.
This has two consequences for the fisetin conversation. First, predicting human efficacy from in vitro fisetin EC50 values — the way the senolytic literature has typically framed the translational question — may understate fisetin’s true biological activity by ignoring geraldol’s contribution. Second, whether the specific senolytic profile of geraldol matches that of fisetin is not fully characterised. Some of the cell-culture assays that established fisetin’s senolytic identity used pure fisetin at defined concentrations; whether the plasma-circulating fisetin plus geraldol mixture in a human dosed adult reproduces this profile is unknown (7).
The geraldol point is not a rescue for the bioavailability ceiling. Even accounting for metabolite activity, the plasma concentrations of both fisetin and geraldol produced by an unformulated oral dose remain well below the in vitro senolytic window. But the metabolite question means the story is somewhat more complex than "fisetin doesn’t reach senolytic concentrations."
Formulation strategies — what actually works
Multiple formulation approaches have been developed to break through the bioavailability ceiling of unformulated fisetin. Each is designed to overcome one or more of the three limiting factors.
Hydrogel encapsulation (FF-20)
The Krishnakumar 2022 study formulation is a hybrid hydrogel of fisetin, galactomannan (a soluble fibre from fenugreek), and a small amount of oil (1). The hydrogel improves aqueous dispersion and may protect the parent compound from first-pass metabolism. The measured 23-fold Cmax improvement is the largest published in a human pharmacokinetic study of fisetin.
Liposomal formulations
Multiple liposomal fisetin products are commercially available. The theoretical basis is that liposome encapsulation improves aqueous dispersion and may enhance lymphatic absorption. Cell-culture and animal data support meaningful improvement in tissue delivery. Human pharmacokinetic data specific to liposomal fisetin are limited. Interestingly, a 2024 cell-culture study of liposome-encapsulated fisetin reported that the liposomal formulation lost senolytic activity and instead reduced the SASP factors IL-6 and IL-8 — a shift from senolytic to senomorphic pharmacology. Our dedicated liposomal fisetin article walks through this in detail.
Nanoemulsion and nanoparticle formulations
Nanoemulsion formulations of fisetin have shown 4- to 24-fold bioavailability improvements in animal studies (6). Polymeric nanoparticles with cyclodextrin inclusion complexes have shown similar gains (5). Neither has been tested in a published human trial.
Piperine co-formulation
Piperine (from black pepper) is a broad-spectrum inhibitor of CYP450 enzymes and Phase II conjugation. It has been used to enhance curcumin bioavailability with substantial effect. Piperine-fisetin co-formulations are commercially available but have not been formally tested in a human pharmacokinetic study. The theoretical basis is sound; the empirical validation is absent.
Co-ingestion with dietary fat
The simplest and most accessible intervention. Fat-soluble flavonoids are absorbed via bile-acid-mediated micellar solubilisation in the intestinal lumen. Adequate dietary fat co-ingestion (~10–15 g at the meal) supports this pathway. No head-to-head trial has directly measured the fat effect on fisetin absorption in humans, but general flavonoid pharmacokinetic principles strongly predict meaningful benefit. Our how and when to take fisetin article covers the practical guidance.
The dose-exposure math — why more isn’t proportionally better
A common reader question: if fisetin absorbs poorly, why not simply take more? The answer sits in the pharmacokinetic ceiling.
The Krishnakumar 2022 study administered 1,000 mg and measured 9.97 ng/ml Cmax. By linear extrapolation, a 2,000 mg dose would produce approximately 20 ng/ml Cmax. Even 5,000 mg — a very high oral dose with substantial GI tolerability concerns — would produce approximately 50 ng/ml Cmax, still 20 to 100-fold below the senolytic window in cell culture. This is because absorption is solubility-limited: increasing the amount of undissolved fisetin in the intestinal lumen does not proportionally increase the amount that dissolves and can be absorbed.
The pulsed protocol is a pragmatic response to this ceiling. Two consecutive high-dose days provide two absorption windows in quick succession, doubling the tissue exposure time above threshold. Beyond that, dose escalation runs into diminishing returns. This is why the Mayo Clinic protocols fixed at 20 mg/kg × 2 days rather than pushing higher (2).
Practical implications for readers
Five practical points fall out of the pharmacokinetic story.
1. Take fisetin with a fat-containing meal. The simplest, most accessible intervention for improving absorption of unformulated capsules.
2. Consider bioavailability-enhanced formulations when available and appropriate. Hydrogel, liposomal, and nanoemulsion formulations produce meaningfully higher plasma concentrations than unformulated capsules. Note that formulation changes may alter pharmacology (senolytic vs senomorphic) as well as kinetics.
3. Do not attempt to compensate for poor bioavailability by taking very high doses. The absorption ceiling means high oral doses produce diminishing plasma gains and rising GI tolerability concerns.
4. The pulsed protocol is a workaround for bioavailability. Two consecutive high-dose days provide the highest achievable exposure from unformulated capsules. See our dedicated pulse dosing article.
5. Read efficacy claims against the pharmacokinetic ceiling. Every claim about what fisetin does in humans must ultimately reconcile with what actually reaches the bloodstream and tissue. Our complete clinician’s guide covers the evidence-tier context.
What we still don’t know
• Whether tissue concentrations exceed plasma concentrations for fisetin in the way that some other lipophilic compounds do. Fisetin has been shown to accumulate in mouse brain (8); whether human tissue accumulation closes the plasma-tissue gap is unmeasured.
• Which formulation strategy produces the best real-world clinical efficacy — not just the highest plasma concentration, but the best senolytic outcome. This has not been tested head-to-head in any human trial.
• Whether piperine, quercetin, or other adjuvants meaningfully improve fisetin absorption in humans. Only in vitro and animal data exist.
• How the metabolism of fisetin differs across populations — CYP2C8 genetic polymorphisms, age-related changes in first-pass metabolism, sex differences. All unstudied.
• Whether the plasma AUC or the Cmax matters more for senolytic efficacy. The pulsed protocol architecture assumes Cmax is the driver; this has not been formally established.
Bottom line
Fisetin is a poorly bioavailable flavonoid. An unformulated oral capsule produces plasma concentrations 30 to 150-fold below the in vitro senolytic window, and no formulation strategy currently in commercial use has been shown to fully close that gap. This does not mean fisetin does nothing — the trials are running specifically because the biology is compelling — but it does mean that every efficacy claim must be interpreted against the pharmacokinetic ceiling. The pulsed protocol, co-ingestion with fat, and bioavailability-enhanced formulations are the three levers a reader has for pushing plasma concentrations closer to biologically relevant levels. None of the three delivers a certainty. Fisetin’s pharmacokinetics are, ultimately, why AFFIRM matters so much: the trial will directly test whether the achievable plasma levels are enough to produce a senolytic effect in tissue. Our dedicated liposomal fisetin article covers the formulation options in more depth.
Frequently asked questions
What is the bioavailability of fisetin?
Poor. A 1,000 mg oral dose of unformulated fisetin produces a peak plasma concentration of just 9.97 ng/ml (1). Absolute oral bioavailability has not been directly measured (no intravenous fisetin study in humans exists), but by comparison to similar flavonoids it is estimated at well under 5%.
Is liposomal fisetin more absorbable?
Preclinical data suggest yes. Human pharmacokinetic data specific to commercial liposomal fisetin products are limited. Cell-culture data suggest that some liposomal formulations may change fisetin’s pharmacology (from senolytic to senomorphic). Our liposomal fisetin article walks through the specifics.
Does fisetin have a long half-life?
No. Fisetin has a short plasma half-life (under two hours by measurement) and does not accumulate meaningfully with daily dosing (1). Continuous exposure at low daily doses does not build up over time in the way that a longer-half-life compound would.
Does fisetin cross the blood-brain barrier?
In mice, yes (8). Human brain penetration has not been directly measured. Given the low plasma concentrations produced by unformulated capsules, brain delivery is likely modest at typical supplement doses.
Is bioavailability different in older adults?
Age-related changes in first-pass metabolism and hepatic clearance are known for many compounds but have not been characterised for fisetin specifically. The AFFIRM population (post-menopausal women) and the Fisetin HIGH population (older multimorbid adults) will help address this.
Should I take piperine or black pepper extract with fisetin?
Theoretically it may enhance absorption; empirically it has not been tested in a published human study of fisetin. Piperine is generally safe at food-level doses. It may modestly increase plasma concentrations of other CYP-metabolised drugs, so caution if you are on prescription medication.
References
1. Krishnakumar IM, Jaja-Chimedza A, Joseph A, et al. Enhanced bioavailability and pharmacokinetics of a novel hybrid-hydrogel formulation of fisetin orally administered in healthy individuals: a randomised double-blinded comparative crossover study. J Nutr Sci. 2022;11:e74. https://doi.org/10.1017/jns.2022.72
2. Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine. 2018;36:18-28. https://pmc.ncbi.nlm.nih.gov/articles/PMC6197652/
3. Touil YS, Auzeil N, Boulinguez F, et al. Fisetin disposition and metabolism in mice: identification of geraldol as an active metabolite. Biochem Pharmacol. 2011;82(11):1731-1739. https://pubmed.ncbi.nlm.nih.gov/21840303/
4. Shia CS, Tsai SY, Kuo SC, Hou YC, Chao PD. Metabolism and pharmacokinetics of 3,3′,4′,7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone, and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. J Agric Food Chem. 2009;57(1):83-89. https://pubmed.ncbi.nlm.nih.gov/19090758/
5. Kadari A, Gudem S, Kulhari H, et al. Enhanced oral bioavailability and anticancer efficacy of fisetin by encapsulating as inclusion complex with HPβCD in polymeric nanoparticles. Drug Deliv. 2017;24(1):224-232. https://pubmed.ncbi.nlm.nih.gov/28156166/
6. Ragelle H, Crauste-Manciet S, Seguin J, et al. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int J Pharm. 2012;427(2):452-459. https://pubmed.ncbi.nlm.nih.gov/22387278/
7. Niedernhofer LJ, Robbins PD. Fisetin as a senotherapeutic agent: evidence and perspectives for age-related diseases. Mech Ageing Dev. 2024;220:111995. https://doi.org/10.1016/j.mad.2024.111995
8. Maher P. Modulation of multiple pathways involved in the maintenance of neuronal function during aging by fisetin. Genes Nutr. 2009;4(4):297-307. https://pubmed.ncbi.nlm.nih.gov/19756810/
9. Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: a dietary antioxidant for health promotion. Antioxid Redox Signal. 2013;19(2):151-162. https://pmc.ncbi.nlm.nih.gov/articles/PMC3689181/